» Articles » PMID: 28545838

Strategies for Targeted Drug Delivery in Treatment of Colon Cancer: Current Trends and Future Perspectives

Overview
Specialty Pharmacology
Date 2017 May 27
PMID 28545838
Citations 77
Authors
Affiliations
Soon will be listed here.
Abstract

Despite advances in treatment modalities, colon cancer (CC) is the third most common cause of cancer-related death worldwide. Subsequent unfavorable effects owing to toxicity of conventional drugs are a challenging problem associated with chemotherapy. There is noticeable concern toward site-specific/targeted delivery of chemotherapeutic drugs specifically to the affected site of the colon in a predictable and reproducible manner. However, the biggest challenge in successful drug targeting for the colon is avoidance of drug absorption and/or degradation in the upper gastrointestinal tract before the drug reaches the colon. Nanoparticles endowed with targeting abilities offer a novel approach for site-specific delivery of chemotherapeutic agents. The present review focuses on recent approaches for colon-specific drug delivery (CDDS) and aims to unveil the emerging possibilities and advances in the treatment of CC with CDDS.

Citing Articles

Advancements in immunotherapy for colorectal cancer treatment: a comprehensive review of strategies, challenges, and future prospective.

Kaviyarasan V, Das A, Deka D, Saha B, Banerjee A, Sharma N Int J Colorectal Dis. 2024; 40(1):1.

PMID: 39731596 PMC: 11682016. DOI: 10.1007/s00384-024-04790-w.


Global research progress of nanomedicine and colorectal cancer: a bibliometrics and visualization analysis.

Tian S, Chen M Front Oncol. 2024; 14:1460201.

PMID: 39711965 PMC: 11660184. DOI: 10.3389/fonc.2024.1460201.


A doxorubicin loaded chitosan-poloxamer implant for the treatment of breast cancer.

Sahoo G, Rai V, Pradhan D, Halder J, Rajwar T, Mahanty R RSC Adv. 2024; 14(46):33952-33967.

PMID: 39463476 PMC: 11503159. DOI: 10.1039/d4ra06253a.


Pancancer analysis of NDUFA4L2 with focused role in tumor progression and metastasis of colon adenocarcinoma.

Zhou R, Sun Z, Zhou R, Wang M, Zhuo Q, Deng X Med Oncol. 2024; 41(11):285.

PMID: 39402288 DOI: 10.1007/s12032-024-02531-1.


Nanomedicine for colon-targeted drug delivery: strategies focusing on inflammatory bowel disease and colon cancer.

Kumar A, Vaiphei K, Singh N, Chigurupati S, Paliwal S, Paliwal R Nanomedicine (Lond). 2024; 19(15):1347-1368.

PMID: 39105753 PMC: 11318742. DOI: 10.1080/17435889.2024.2350356.